Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.

Summary

In two parallel, double-blind RCTs totaling 1,061 patients with severe hypertriglyceridemia, monthly olezarsen reduced triglycerides by roughly 50–72 percentage points vs placebo at 6 months and significantly lowered acute pancreatitis incidence (rate ratio 0.15). Safety was acceptable overall, though higher-dose (80 mg) was associated with more liver enzyme elevations, thrombocytopenia, and increased hepatic fat fraction.

Key Findings

• At 6 months, placebo-adjusted triglyceride reduction ranged from −49.2 to −72.2 percentage points across trials and doses (P<0.001).
• APOC3, remnant cholesterol, and non-HDL cholesterol decreased significantly vs placebo at 6 and 12 months.
• Acute pancreatitis incidence was significantly lower with olezarsen (mean rate ratio 0.15; 95% CI 0.05–0.40).
• Higher-dose (80 mg) showed more elevations in liver enzymes, thrombocytopenia, and a dose-dependent increase in hepatic fat fraction.

Clinical Implications

Olezarsen offers a disease-modifying option for severe hypertriglyceridemia to prevent pancreatitis. Clinicians should consider dose selection and monitor liver enzymes, platelet counts, and hepatic fat, particularly at 80 mg.

Limitations

• Safety signals at higher dose (liver enzymes, thrombocytopenia, hepatic fat) may constrain dosing
• Follow-up duration limited to 12 months; long-term outcomes and generalizability beyond severe hypertriglyceridemia remain to be defined

Future Directions

Define optimal dosing balancing efficacy and safety, assess long-term pancreatitis and cardiovascular outcomes, and evaluate combination strategies with dietary and other lipid-lowering therapies.